BioCon Limited
20th KM Hosur Road
Electronics City
Bangalore
560 100
Tel: 90-80-2808-2808
Fax: 91-80-2852-3423
Website: http://biocon.com/
Email: contact.us@biocon.com
69 articles about BioCon Limited
-
A new report by PwC projects that the second half of this year will see a “flurry of deals activity across all areas of the sector.”
-
Biocon Biologics has acquired its partner Viatris’ biosimilars assets. The transaction is part of an effort to create a global, vertically-integrated biosimilars leader.
-
Mylan and Biocon Biologics Announce Launch of Semglee™ (insulin glargine injection) in the U.S. to Expand Access for Patients Living with Diabetes
8/31/2020
Semglee available in vial and pen presentations at a 65% discounted list price, the lowest available for a long-acting insulin glargine on the market
-
Clinical Trial Shows Itolizumab Reduces Mortality in Patients Hospitalized with COVID-19
7/13/2020
Equillium, Inc., a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, announced that as reported by its partner, Biocon Limited, a clinical trial conducted in India by Biocon demonstrated that itolizumab significantly reduced mortality in patients hospitalized with COVID-19.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 13, 2020.
-
Biocon Biologics Appoints M.B. Chinappa as Chief Financial Officer
1/6/2020
Biocon Ltd,, an innovation-led global biopharmaceuticals company, announced that it has appointed Mr. M.B. Chinappa as Chief Financial Officer of its subsidiary Biocon Biologics India Ltd.
-
Biocon Biologics Takes Forward Its Mission to Unlock UniversalAccess to Insulins Globally
12/3/2019
Participating at IDF Congress 2019, Busan, to Engage with Key Stakeholders
-
Biocon Features in the Prestigious ASIA IP ELITE List for the Fourth Consecutive Year
11/12/2019
Biocon Ltd announced that it has been recognised as the ASIA IP ELITE for the fourth year in a row and its wholly-owned subsidiary Biocon Biologics makes its debut on this prestigious list in 2019 by the IP Business Congress Asia for robust Intellectual Property management and consistent IP value creation.
-
Biocon’s Biologics Drug Products Facility in Bengaluru Receives EIR from U.S. FDA
11/5/2019
Reaffirms Biocon’s Capability to Manufacture Biosimilars for Patients in U.S.
-
Biocon Biologics & Just - Evotec Biologics Sign Licensing Deal for a Biosimilar Asset
10/10/2019
Biocon Biologics in-licenses an early-stage biosimilar asset, will undertake development, manufacturing and commercialization under its own label
-
Biocon Biologics Expands its R&D Footprint Through Acquisition
9/24/2019
60,000 sq. ft World-class Integrated R&D Facility at TICEL Bio Park to House 250 scientists
-
Biocon Licenses Three Generic Formulation Products to China Medical System Holdings
9/12/2019
Agreement Extends Biocon’s Footprint to Greater China, the World’s 2nd Largest Pharma Market
-
Biocon’s Malaysia Insulin Glargine Manufacturing Facility Receives EU GMP Certification, Provides Fillip to its Capacity
8/22/2019
Biocon Ltd, Asia’s premier biopharmaceuticals company, Biocon Ltd announced that it’s subsidiary in Malaysia, Biocon Sdn.
-
Mylan and Biocon to Present Final Overall Survival Data for Ogivri™ (trastuzumab-dkst), a biosimilar to Herceptin®, at the American Society of Clinical Oncology (ASCO) Annual Meeting
5/15/2019
Ogivri™ is the first biosimilar for Herceptin® approved by the U.S. Food and Drug Administration (FDA) for all indications including HER2-positive breast and gastric cancers [15-May-2019] HERTFORDSHIRE, England and PITTSBURGH and BENGALURU, India , May 15, 2019 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced
-
Mylan and Biocon Announce Positive CHMP Opinion for Ogivri®, Biosimilar Trastuzumab
10/19/2018
Mylan N.V. and Biocon Ltd. today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Ogivri®, a biosimilar to Roche's Herceptin® (trastuzumab).
-
In a brief statement, Mylan reported that the U.S. Food and Drug Administration (FDA) had informed the company that its Generic Advair Diskus had “minor deficiencies” that would be in a Complete Response Letter.
-
The U.S. Food and Drug Administration (FDA) approved Mylan’s Fulphila (pegfilgrastim-jmbd), a biosimilar to Amgen’s Neulasta (pegfilgrastim). The biosimilar was co-developed with Biocon.
-
U.S. FDA Approves Mylan and Biocon's Fulphila™ (pegfilgrastim-jmdb), the First Biosimilar to Neulasta®
6/4/2018
Mylan N.V. and Biocon Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved Mylan's Fulphila™ (pegfilgrastim-jmbd).
-
Mylan and Biocon to Present New Data at the American Society of Clinical Oncology (ASCO) Annual Meeting Reinforcing the Efficacy, Safety and Immunogenicity of Ogivri™, the first biosimilar for Herceptin® approved by FDA
6/1/2018
Mylan N.V. and Biocon Ltd. announced that 48-week results from the HERITAGE study will be presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.
-
The FDA Giveth and Taketh Away: Grants Pfizer's MenB Breakthrough Therapy Designation and Turns D...
4/23/2018
The FDA granted Pfizer’s Trumenba, a vaccine for meningococcal B disease in children ages one to nine years, Breakthrough Therapy Designation and declined to approve its biosimilar of Roche's Herceptin for breast cancer.